{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-054774","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.836161+00:00","generated_at":"2026-06-16T03:37:50.507479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch","bullets":["Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).","Over 300 new BBS prescriptions for IMCIVREE since June 2022 FDA approval; >100 written in Q1 2023.","First patients dosed in pivotal Phase 3 hypothalamic obesity trial; enrollment completion expected Q1 2024.","Cash position $294.6M at March 31, 2023, down from $333.3M; FY 2023 Non-GAAP OpEx guidance $200-220M.","Launched IMCIVREE in Germany for BBS with federal reimbursement on April 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-054774","json":"https://secwatch.observer/filing/0001104659-23-054774.json","markdown":"https://secwatch.observer/filing/0001104659-23-054774.md","text":"https://secwatch.observer/filing/0001104659-23-054774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/0001104659-23-054774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/tm2314243d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:37:50.507479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a729de0a0f8b67a3700fbc26612725a63f1f9e82","claim":"RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2023 results: revenue $11.5 million.","evidence_excerpt":"Net product revenues relating to global sales of IMCIVREE were $11.5 million for the first quarter of 2023, as compared to $1.5 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/0001104659-23-054774-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$11.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}